Title:
川崎病の診断及び治療
Document Type and Number:
Japanese Patent JP6779200
Kind Code:
B2
Abstract:
Described is a method of diagnosing, treating, or monitoring a treatment for Kawasaki disease in a subject. The method includes detecting the level of a biomarker in a sample obtained from the subject, the biomarker being IL-7F, sCD40L, MPIF-1, E-selectin, IP-10, or IL-33. The level is compared to a cut-off level. Also described is a kit for carrying out the method.
More Like This:
Inventors:
Cheng Yuen-Chung
Woo Jae-Youn
Koutai-Min
Quo-Fo-Chan
Chang Jen-Shen
Woo Jae-Youn
Koutai-Min
Quo-Fo-Chan
Chang Jen-Shen
Application Number:
JP2017503621A
Publication Date:
November 04, 2020
Filing Date:
July 23, 2015
Export Citation:
Assignee:
ACADEMIA SINICA
International Classes:
G01N33/53; A61K31/573; A61K39/395; A61P9/00; C12Q1/04; G01N33/543
Foreign References:
| US20130316921 | ||||
| US20110189698 | ||||
| US20130315911 |
Other References:
上砂光裕ほか,川崎病における血清サイトカイン,ケモカインの変化,第45回日本小児循環器学会総会・学術集会プログラム,2009年,I-P-83,URL,http://jspccs.jp/archive/site/html_m/journal/journal_mtg/20092503/715p2/83.html
SHIKISHIMA, Y. et al.,Chemokines in Kawasaki disease: measurement of CCL2, CCL22 and CXCL10,Asian Pacific journal of allergy and immunology,2003年,Vol. 21, No. 3,pp. 139-143
WANG, C.-L. et al.,Expression of CD40 Ligand on CD4+ T-Cells and Platelets Correlated to the Coronary Artery Lesion and Disease Progress in Kawasaki Disease,PEDIATRICS,2003年 2月,Vol. 111, No. 2,pp. e140-147
CHEN, G. et al.,Change in plasma level of soluble E- selectin and +A561C polymorphisms in children with kawasaki disease,International Journal of Rheumatic Diseases,2010年,Vol. 13, Suppl. 1,p. 59, 0006
JIA, S. et al.,The T helper type 17/regulatory T cell imbalance in patients with acute Kawasaki disease,Clinical and Experimental Immunology,2010年,Vol. 162,pp. 131-137
LEE, D.W. et al.,NT-proBNP as a useful tool in diagnosing incomplete Kawasaki disease,Korean Journal of Pediatrics,2010年,Vol. 53, No. 4,pp. 519-524
Swati Singhal,Primary Treatment of Kawasaki Disease with Corticosteroids,Journal of Clinical and Diagnostic Research,2014年 5月,Vol.8 No.5,Page.PD04-PD05
DAVID M. WONG,Guidelines for the Use of Antibiotics in Acute Upper Respiratory Tract Infections,American Family Physician,2006年 9月15日,Vol.74 No.6,Page.956-966
SHIKISHIMA, Y. et al.,Chemokines in Kawasaki disease: measurement of CCL2, CCL22 and CXCL10,Asian Pacific journal of allergy and immunology,2003年,Vol. 21, No. 3,pp. 139-143
WANG, C.-L. et al.,Expression of CD40 Ligand on CD4+ T-Cells and Platelets Correlated to the Coronary Artery Lesion and Disease Progress in Kawasaki Disease,PEDIATRICS,2003年 2月,Vol. 111, No. 2,pp. e140-147
CHEN, G. et al.,Change in plasma level of soluble E- selectin and +A561C polymorphisms in children with kawasaki disease,International Journal of Rheumatic Diseases,2010年,Vol. 13, Suppl. 1,p. 59, 0006
JIA, S. et al.,The T helper type 17/regulatory T cell imbalance in patients with acute Kawasaki disease,Clinical and Experimental Immunology,2010年,Vol. 162,pp. 131-137
LEE, D.W. et al.,NT-proBNP as a useful tool in diagnosing incomplete Kawasaki disease,Korean Journal of Pediatrics,2010年,Vol. 53, No. 4,pp. 519-524
Swati Singhal,Primary Treatment of Kawasaki Disease with Corticosteroids,Journal of Clinical and Diagnostic Research,2014年 5月,Vol.8 No.5,Page.PD04-PD05
DAVID M. WONG,Guidelines for the Use of Antibiotics in Acute Upper Respiratory Tract Infections,American Family Physician,2006年 9月15日,Vol.74 No.6,Page.956-966
Attorney, Agent or Firm:
Patent Business Corporation Saegusa International Patent Office